Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRX302 for Benign Prostatic Hyperplasia
NCT00889707Phase 2Completed
- Sponsor
- Sophiris Bio Inc.
- Start
- Jan 2009
- Primary completion
- Dec 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of topsalysin in benign prostatic hyperplasia (BPH) (2 arms), sponsored by Sophiris Bio Inc. Primary endpoint: Change in International Prostate Symptom Scale at 3 months. Started Jan 2009; status: completed.
02
Drugs
topsalysin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT00889707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00889707.